OptiMax™ STAT

About MiCo BioMed USA

MiCo BioMed USA is a private, commercial-stage diagnostics company leveraging its proprietary Optimiser™ microfluidic technology to enhance immunoassay performance across multiple settings, from point-of-care to automated labs. The company offers an open-source platform that allows for the transfer of existing ELISA protocols with minimal reagent changes, claiming significant improvements in sensitivity, speed, and sample volume. With over 70 assays validated on its platform and products commercially available for the life science market, MiCo is seeking strategic partnerships to expand into the clinical diagnostics sector. Its strategy targets cost-sensitive and throughput-constrained segments of the global diagnostics market.